MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1016/j.transproceed.2022.08.027

Медицинская библиотека · Transplantation proceedings · 2022

Everolimus Use in Lung Transplant Recipients.

Turkkan Sinan, Basaran Fatmanur Celik, Sahin Mehmet Furkan, Beyoglu Muhammet Ali, Yilmaz Emre, Ozay Hülya Yigit, Bindal Mustafa, Yazicioglu Alkin, Yekeler Erdal

Наблюдательное исследованиеСтатьяПеревод в очереди

Аннотация

BACKGROUND

Most lung transplantation centers prefer triple immunosuppressive therapy with tacrolimus, mycophenolate mofetil, and corticosteroids. However, to prevent complications and comorbidities caused by tacrolimus, replacing the drug with everolimus has been considered.

METHODS

This is a retrospective observational study investigating everolimus switch for different reasons. The population was divided into 3 groups: chronic lung allograft dysfunction (CLAD), kidney impairment, and malignant neoplasm groups. We investigated whether we achieved the goal of the switch and the frequency of rejection, cytomegalovirus and fungal infections, and everolimus adverse effects.

RESULTS

Nineteen patients received everolimus therapy, and 5 of these were for CLAD, 7 for tacrolimus nephrotoxicity, and 7 for explant/de novo malignant neoplasm. The patients were followed up for a mean (SD) of 30 (16.7) months under the therapy. The number of acute cellular rejection, cytomegalovirus infection, and aspergillosis infection cases before switch were 7, 13, and 2, respectively, and 7, 2, and 3 after that. The mean values of creatinine and estimated glomerular filtration rate of the whole population after the switch improved with no statistical significance, whereas it was significant in tacrolimus nephrotoxicity group. Three patients in the CLAD group remained stable after switching, whereas 2 progressed. Only 1 of the 7 patients with malignant neoplasms had a recurrence during 31.1 (16.5) months of median follow-up. Eleven cases of everolimus adverse effects occurred in 9 patients (47.3%), with 2 (10.5%) withdrawal events. Kidney impairment (P = .02) and age (P = .05) stood out as significant risk factors for drug adverse effects.

CONCLUSIONS

After lung transplant, everolimus can be a safe alternative for immunosuppression with acceptable adverse effects.

Для цитирования: Turkkan Sinan, Basaran Fatmanur Celik, Sahin Mehmet Furkan, Beyoglu Muhammet Ali, Yilmaz Emre, Ozay Hülya Yigit, Bindal Mustafa, Yazicioglu Alkin, Yekeler Erdal. Everolimus Use in Lung Transplant Recipients.. Transplantation proceedings. 2022. DOI: 10.1016/j.transproceed.2022.08.027.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.